ArticleFrontiers in oncology2026
Differential expression of immune activation markers in T cells from patients with multiple myeloma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple myeloma (MM) is the second most common hematological malignancy, characterized by the abnormal proliferation of malignant plasma cells leading to the classic CRAB symptoms. Despite advances in treatment, MM remains incurable. Alterations in the tumor immune microenvironment (TIME) contribute to therapy resistance. However, the activation status of T cells, key regulators of immune responses, is still not fully understood in MM. Methods: To further investigate immune alterations in the tumor microenvironment, bone marrow samples were collected from 18 newly diagnosed MM patients and 12 age- and sex-matched healthy controls. Multiparameter flow cytometry was used to analyze T cell subsets and their activation markers. Results: We observed a significant increase in the proportions of CD4 Discussion: These findings reveal differences in the composition and activation profiles of T cell subsets in the bone marrow of MM patients. While they provide insights into the immune landscape of MM, further studies are needed to clarify their functional significance and potential implications for therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.